Blog

  • ExpressVPN switches to multi-tiered pricing plans, letting users tweak features to plan duration

    ExpressVPN switches to multi-tiered pricing plans, letting users tweak features to plan duration

    ExpressVPN has tripled its subscription options by switching to a tiered pricing structure, effective today. The new system includes three levels of service, the cheapest offering basic VPN service and the others adding extra features. Each one of those levels — Basic, Advanced and Pro — can be purchased for monthly, yearly or two-year durations.

    In total, you’ve now got nine different options for subscribing to ExpressVPN. The company also says legacy plans will remain active “for now,” and current customers won’t be downgraded. The change is similar to the approach already used by rivals like NordVPN and Surfshark.

    Previously, ExpressVPN locked feature offerings to the duration of the plan, so the only way to get the full suite of features was to subscribe for 24 months. Now, while longer-term subscriptions will still offer discounts, features depend on your level of subscription instead of how long it lasts.

    The new tiers roll in some features that were previously part of ExpressVPN’s Identity Defender suite, including identity monitoring, credit reports and data removal services. New types of plans will also bump the number of allowed simultaneous connections to as high as 14. Here’s what you’ll get with each tier.

    The Basic plan comes with “core VPN functionality” including the Lightway protocol. Basic users will no longer have access to the ad blocker, tracker blocker or parental controls. It can be used on 10 devices at once and will cost $12.99 for a month, $74.85 for a year and $97.72 for two years.

    The Advanced plan raises the device limit to 12 and adds the blockers and parental controls, plus the ExpressVPN Keys password manager. It also gives you three days of eSIM service and adds the Identity Defender features — leak alerts, $1 million of identity theft insurance, data removal and credit monitoring. As was already the case, those ID protection features are available only to users in the United States.

    An Advanced plan will cost $13.99 for a month, $89.85 for a year and $125.72 for two years. The one-year and two-year plans are both cheaper than the same duration used to cost. Advanced subscribers also get five days of eSIM service and a discount coupon for between 25 and 50 percent off an ExpressVPN Aircove router (it’s not currently clear how the exact discount will be determined).

    Although Basic and Advanced users can pay extra (between $3.99 and $8.99) for a dedicated IP address, it comes standard on a Pro subscription. Pro users additionally get monthly credit reports and data removal, 14 simultaneous connections and an Aircove discount between 50 and 75 percent. A Pro plan costs $19.99 for a month, $134.95 for a year and $209.72 for two years.

    What ExpressVPN tiered pricing means for VPN shoppers

    Ultimately, I don’t think this new approach will change much about the experience of using ExpressVPN. It’s not introducing any new features; I already touched on everything here in my recent ExpressVPN review, so the only difference is how much you’ll pay to access the perks.

    The best news for consumers is that ExpressVPN is now available for significantly cheaper than before. A two-year Basic plan costs about 30 percent less than a two-year subscription used to — though a one-year basic plan is still more expensive than a comparable subscription to Proton VPN or Surfshark. All that said, I can’t enthusiastically recommend a Basic subscription until I know that it includes the Network Lock kill switch and split tunneling on supported platforms (we’re reaching out to ExpressVPN to confirm this).

    We’re in the process of overhauling our ranking of best VPNs, including the new information from ExpressVPN — check in soon to see the results.

    Continue Reading

  • Seth Rogen Hits Venice Film Festival in Research Mode for ‘The Studio’

    Seth Rogen Hits Venice Film Festival in Research Mode for ‘The Studio’

    Matt Remick falling off a water taxi outside the Excelsior? Matt Remick being kicked out of his own party at the Cipriani by an angry Italian bouncer? Matt Remick desperately trying to work an unenthused crowd into giving his terrible out-of-competition film a half-decent standing ovation? Keep an eye on the next season of Apple TV+’s entertainment industry satire “The Studio” as these scenes may well make it in.

    Seth Rogen — who co-created the show and plays fictitious studio head Remick — was in research mode at the Venice Film Festival on Monday. Though he’s not involved with A24’s “The Smashing Machine,” he attended the afternoon press conference for the Dwayne Johnson’s wrestling drama before hitting the red carpet for the world premiere. During the film’s 15-minute standing ovation (something Remick’s Continental Studios could only dream of), while Johnson and Safdie both wept for joy, Rogen — sat a few rows back from the main stars — spent much of the time capturing footage on both his phone and a chunky digital camera (and also cheering and merrily posing for the occasional selfie with fans). He later carried on to the after party, where he chatting to fellow guests — and took more photos, with organizers telling Variety that he’d been dubbed “The Snapping Machine.”

    Speaking to Italian website Adnkronos, Rogen said he was at the festival “scouting locations” for “The Studio” season two, which was announced in May by Apple TV+.

    Rogen’s reps didn’t immediately respond to Variety’s request for comment.

    While a Golden Lion might be some way off for Remick and Continental, “The Studio” series could be headed towards Emmys glory. Its 23 nominations broke records for a comedy in its first season, and tied the record set by “The Bear” last year as the most nominated comedy series ever.

    For all the insider-y laughs, however, “The Studio” recently came under fire by a real-life studio boss, Sony’s Tom Rothman, who told Letterboxd that there was a “kernel of brilliant, blinding truth” in each episode, but “everything else is horse shit.”

    How that barb will manifest in the shenanigans of season two is anyone’s guess.

    Continue Reading

  • How magnets could help astronauts explore the moon and Mars

    How magnets could help astronauts explore the moon and Mars

    Scientists have developed a more efficient way to generate oxygen for astronauts that could help with future missions into deep space.

    Current life-support systems such as those on the International Space Station (ISS) rely on bulky centrifuges to separate the oxygen and hydrogen bubbles created when water is split by electricity, a process known as electrolysis. On Earth, bubbles rise away from electrodes, but in microgravity, spinning is required to separate them. This method works, but the equipment is heavy, power-hungry and is ill-suited for long-duration missions to the moon or Mars.

    Continue Reading

  • Neurophet Signs MoU with InRAD to Establish Global Standards for Alzheimer’s disease and Dementia Data

    Neurophet Signs MoU with InRAD to Establish Global Standards for Alzheimer’s disease and Dementia Data

    • Neurophet’s AI-based brain imaging analysis solutions to support global standardization of Alzheimer’s and other dementia-related data
    • Enhancing dementia research by integrating AI imaging solutions with real-world data platforms

    SEOUL, South Korea, Sept. 2, 2025 /PRNewswire/ — Neurophet (Co-CEOs Jake Junkil Been and Donghyeon Kim), an artificial intelligence (AI) solution company for brain disorders diagnosis and treatment, announced today that it has signed a Memorandum of Understanding (MoU) with the International Registry for Alzheimer’s Disease and Other Dementias Foundation (InRAD) to accelerate global standardization of Alzheimer’s and dementia-related data.




    Neurophet Signs MoU with InRAD to Establish Global Standards for Alzheimer’s disease and Dementia Data






    Neurophet Signs MoU with InRAD to Establish Global Standards for Alzheimer’s disease and Dementia Data

    Through this agreement, Neurophet and InRAD aim to strengthen their collaboration to help establish globally harmonized standards for Alzheimer’s disease and other dementias real-world data1. The partnership also seeks to enable the seamless integration of AI-based neuroimaging technologies into the broader real-world data landscape, removing one of the key practical barriers to evidence generation – namely, the lack of coordinated approaches – while acknowledging the wider adoption of these technologies in everyday clinical practice.

    The partnership will focus on key initiatives including:

    • Enhancing clinical workflows involving MRI and PET analysis
    • Collecting and aggregating clinical imaging and quantitative data
    • Validating clinical utility of AI-based analysis solutions
    • Developing joint research and education programs

    Neurophet’s flagship products — Neurophet AQUA AD, an Alzheimer’s Disease Treatment Prescription/Treatment Effect and Side Effect Monitoring Software; and Neurophet SCALE PET, a PET Image Quantitative Analysis Software; and Neurophet AQUA, a Brain MRI Analysis Software — will be available for utilization in this collaboration.

    InRAD, is a free at the point-of-use registry that enables the collection of real-world data to further understanding about Alzheimer’s disease, and in the future, other dementias and to support clinical management. The registry is coordinated by the independent International Registry for Alzheimer’s Disease and Other Dementias Foundation, a health-related not-for-profit entity incorporated in the Netherlands. The registry platform will launch later in 2025, providing a secure, regionally compliant, Azure cloud-based registry platform and governance package.

    Notably, InRAD has a board composed of globally renowned researchers and clinicians in the field of dementia, including Professor Philip Scheltens, a leading expert who established the MTA scale (also known as the Scheltens scale) — the world’s first MRI-based diagnostic framework for Alzheimer’s disease. Professor Scheltens commented, “Collaborations such as these help to ensure a joined-up approach, reducing barriers to real world data collection in clinical practice and supporting patient care. We are very pleased to be able to announce this MoU”.

    Jake Junkil Been, Co-CEO of Neurophet, commented,

    “This partnership marks a significant step toward expanding the clinical adoption and credibility of Neurophet’s AI-powered brain imaging analysis tools on a global scale. We are committed to support clinicians and researchers worldwide by enabling standardized access to high-quality Alzheimer’s disease datasets.”

    Neurophet continues to lead the medical AI field by forging strategic partnerships with global healthcare stakeholders.

    About Neurophet

    Neurophet has specialized in developing solutions for diagnosis support, treatment guides, and treatment devices targeting brain disorders based on cutting-edge artificial intelligence (AI) technology. The company was founded in 2016 by Co-CEOs Jake Junkil Been and Donghyeon Kim, who developed the next-generation neuro-navigation system.

    Major products include brain MRI analysis software “Neurophet AQUA”, PET Image Quantitative Analysis Software “Neurophet SCALE PET”, Brain imaging treatment planning software for electric brain stimulation “Neurophet tES LAB”, Alzheimer’s Disease treatment prescription and monitoring software “Neurophet AQUA AD” for tracking treatment efficacy and side effects, and Multiple Sclerosis image analysis software “Neurophet AQUA MS”.

    Neurophet has set its top priority to helping patients suffering from brain disorders. Based on expertise in neuroscience, Neurophet will continue to challenge and grow to explore the human brain’s health and pioneer solutions for brain diseases with AI technology.

    1.  Perneczky et al. Real-world datasets for the International Registry for Alzheimer’s Disease and Other Dementias (InRAD) and other registries: An international consensus, The Journal of Prevention of Alzheimer’s Disease 2025 https://doi.org/10.1016/j.tjpad.2025.100096

    SOURCE Neurophet

    Continue Reading

  • Panasonic Redefines 4K Production with New AK-UBX100 Multi-Purpose Camera and World’s First Auto-Focus for 4K Studio Cameras | Panasonic North America

    Newark, NJ – Panasonic Video and Audio Systems North America, a business unit of Panasonic Connect of North America, today unveiled the AK-UBX100, a next-generation 4K box-style multi-purpose camera designed to give broadcasters, houses of worship, live event producers, and content creators more freedom, precision, and consistency in their productions. Alongside the launch, Panasonic announced the world’s first1 auto-focus (AF) capability for 4K studio cameras, coming to the flagship AK-UCX100 via firmware update in December 2025.

    As live production continues to evolve with LED walls, immersive projection, sophisticated lighting, and the growing demand for seamless live streaming, producers need solutions that simplify operations while maintaining uncompromising quality. The AK-UBX100 was purpose-built to meet those needs, offering creative versatility with a lightweight design that makes it one of the most flexible cameras in its class. Sharing the same platform and 2/3 bayonet lens mount as the AK-UCX100 studio camera, it ensures seamless color matching and unified operability across Panasonic’s ecosystem. A shared Remote Operation Panel connects the AK-UBX100 with the AK-UCX100 and the AW-UE160 4K PTZ camera, streamlining workflows and reducing setup time.

    The AK-UBX100 supports leading IP standards including SMPTE ST 2110, NDI® High Bandwidth2, SRT and features dual 12G-SDI and SFP+/28 interfaces for uncompromising connectivity. An optional HD optical low-pass filter3 minimizes moiré on LED walls, delivering crisp, expressive images even in challenging environments. Its compact, flat-sided design also makes it highly compatible with robotic systems and easy to integrate into a variety of production settings.

    In parallel, Panasonic is introducing the industry’s first auto-focus functionality for 4K studio cameras. This breakthrough, available first on the UCX100 through a firmware update in December 2025, enables fast, stable, and accurate focus acquisition across a wide variety of lenses, helping operators of all skill levels capture sharp, professional results. The feature allows adjustment of focus area, size, and speed, while also supporting smooth handoff to manual operation for more experienced users. AF functionality will expand to the UBX100 via firmware in Q2 CY2026, extending its capabilities even further.

    “The UBX100 is a powerful addition to Panasonic’s camera lineup, giving production teams a lightweight, versatile, and IP-friendly tool that delivers consistent quality,” said Jim Jensen, Senior Product Manager at Panasonic Video and Audio Systems North America. “Alongside our breakthrough auto-focus for the UCX100, we’re empowering creators to focus less on technical challenges and more on telling their stories.”

    The AK-UBX100 and auto-focus capability for 4K studio cameras will debut at IBC2025 in Amsterdam, September 12–15, where attendees can experience its capabilities firsthand.

    Continue Reading

  • MOVA Z60 Ultra Roller Complete Delivers Hands-Off, Hygienic Cleaning with Real-Time Mop Washing and Carpet-Safe Intelligence

    MOVA Z60 Ultra Roller Complete Delivers Hands-Off, Hygienic Cleaning with Real-Time Mop Washing and Carpet-Safe Intelligence

    MOVA, the smart home innovator gaining great interest by North American consumers, announces the Z60 Ultra Roller Complete—delivering unrivaled premium features at breakthrough value and setting a new benchmark for flagship smart home cleaners.

    HONG KONG, Sept. 2, 2025 /PRNewswire/ — Today, MOVA debuts the Z60 Ultra Roller Complete—an AI-powered smart roller mop robot vacuum built for busy families, pet owners, and any home needing real cleaning power. By fusing advanced engineering, true hands-off automation, and effortless carpet-safe hygiene, MOVA finally delivers what smart cleaning should be. This latest innovation joins MOVA’s award-winning portfolio, demonstrating MOVA’s commitment to smarter, better-value cleaning for every home.




    With HydroForce™ real-time self-cleaning roller mopping, AutoShield™ carpet-safe protection, and 28,000Pa suction, the MOVA Z60 Ultra Roller Complete delivers a truly hands-off, hygienic clean across mixed surfaces.






    With HydroForce™ real-time self-cleaning roller mopping, AutoShield™ carpet-safe protection, and 28,000Pa suction, the MOVA Z60 Ultra Roller Complete delivers a truly hands-off, hygienic clean across mixed surfaces.

    Following its September 2nd announcement, the Z60 Ultra Roller Complete will be showcased at MOVA’s booth during IFA Berlin 2025, offering attendees and media the chance to see its capabilities in action. “This isn’t just a better robot vacuum—it’s the ultimate solution for all-in-one hands-off cleaning, deep mopping, thoughtful carpet care, and next-level AI automation,” says Jiajia Chen, Head of Marketing, MOVA North America. “The Z60 is smart floor care that’s exciting, trustworthy and easy for homeowners—as it should be!” 

    Unparalleled Consumer Benefits: Zero Chores, Zero Compromises
    Sick of spending evenings wrangling floor dust, dirty mop water, and damp carpet edges? MOVA Z60 Ultra Roller Complete lets you forget floor chores entirely. HydroForce™ Roller Mopping brings a high-pressure, 12-nozzle system that keeps its 10.08-inch roller mop scrubbing with real-time clean water—and crucially, instantly sucks up dirty water before it ever touches other surfaces. No smear, no tired mop dragging old messes across your floors—just true, sanitized cleaning, every cycle.

    Z60 raises the standard when it comes to carpet protection. Never worry about soaking rugs or prepping rooms in advance. AutoShield™ technology instantly detects soft surfaces, lifts the mop by 0.55-inch, and drops a moisture-cutting shield—ensuring carpets remain protected and dry, every pass, every surface. It’s intelligent, automatic, and totally risk-free.

    And edge cleaning? Finally solved. MaxiReach™ arms extend side brushes and the roller, delivering 99.99% actual edge coverage. MOVA tackles forgotten baseboards, tight furniture lines, and corner crumbs with precision.

    Breakthrough Innovation for Real Homes
    The Z60 isn’t just powerful, it’s quietly spectacular. Its TurboForce 9 Motor delivers a staggering 28,000Pa suction—enough muscle to pull pet hair and dust from stubborn cracks and shaggy carpets, yet running whisper-quiet. The TroboWave™ DuoBrush, a dual-roller anti-tangle system, keeps long hair (up to nearly one foot long!) and thick fuzz from winding up and choking the brush. This is the game-changer for families with pets.

    No more getting stuck at thresholds: StepMaster™ 2.0 combined with LiftPro™ Chassis powers over bumps and transitions up to 3.15-inch tall (essentially the height of two small steps), so moving between tile, hardwood, and carpeted rooms isn’t a challenge. The industry-first Fluffing Roller Technology restores the mop’s cleaning texture after every use, working faster than any other brand at 900-1000RPM, keeping deep-clean effectiveness locked in, cycle after cycle.

    FlexScope™ Navigation adapts the height of the vacuum’s sensor system for smarter mapping and more effective cleaning in various home environments. The DToF (Direct Time-of-Flight) sensor can retract, allowing the Z60 to clean tight or low-clearance spaces, such as under low furniture or kitchen cabinets, thanks to its compact height. When in open spaces, the DToF sensor extends, providing 360° precise mapping, improved navigation, and detailed cleaning path planning, which helps the vacuum detect and clean messes more accurately with better overall control.

    Built With Purpose: Best Robot Mop of 2025
    This is what smart home cleaning robotics should have looked like all along: not just features, but solutions to years of user pain points—messy carpets, tangled brushes, neglected edges, and fake clean. MOVA’s customizable DuoSolution™ dual tanks target odors and stains, select cleaning zones in the app, and flex power for exactly what—and where—you need most. Pet-specific modes? Done. Mixed surfaces and wild messes? No sweat. The result: genuine real-time mop self-cleaning, AI-powered carpet safeguarding, and industry-best suction, all in a hands-off, hygienic robot. Best-in-class features usually mean sky-high prices or vaporware promises. MOVA changes that. The Z60 combines intelligent design and everyday usability at a competitive value, currently unmatched.

    What sets MOVA Z60 Ultra Roller Complete apart?

    • True real-time self-cleaning mop – HydroForce™
    • AI-powered, risk-free carpet protection – AutoShield™
    • Industry-leading suction and anti-tangle technology – 28,000Pa + TroboWave™ DuoBrush
    • 99.99% edge-to-edge cleaning coverage – MaxiReach™
    • Up to 3.15-inch obstacle clearance – StepMaster™ 2.0 + LiftPro™ Chassis
    • 360° precise mapping and detailed cleaning path planning – FlexScope™
    • Customizable, app-driven cleaning strategies—including “Pet Mode”
    • Genuinely hands-off experience at competitive launch pricing

    TLDR: With MOVA Z60 Ultra Roller Complete, home cleaning robots finally deliver on the pledge: full automation, true hygiene, and carpet-safe versatility—all designed for the way families actually live.

    Pricing and Availability
    United States
    The MOVA Z60 Ultra Roller Complete will be available beginning September 16, 2025 at a launch promo price of $1,199 USD (MSRP $1,499). The promotional     offer runs through September 25, 2025, at MOVA’s official U.S. site and Amazon.com.

    Canada
    The MOVA Z60 Ultra Roller Complete will be available beginning September 25, 2025 at a launch promo price of $1,599 CAD (MSRP $1,999). The promotional offer     runs through October 6, 2025, at MOVA’s official Canadian site and Amazon.ca.

    Each Z60 Ultra Roller Complete package includes a premium accessory kit with bonus mop pads, brushes, dust bags, filters, and full-size cleaning solutions, plus comprehensive support for one year of worry-free operation for ultimate value. In addition, its 3-year warranty provides long-term reliability and peace of mind for users.

    About MOVA
    Founded in 2024, MOVA creates intelligent products that think and clean on their own—freeing people from daily chores and giving them more time for what matters most. From floor care and personal grooming to kitchen essentials and outdoor tools, MOVA is building a connected ecosystem designed to bring ease and comfort to every corner of life. Backed by advanced engineering and guided by human needs, MOVA is redefining the home experience and shaping the future of smart living.

    SOURCE MOVA

    Continue Reading

  • Molecule Shows Promise for MASH, Endometriosis, and Other Chronic Diseases < Yale School of Medicine

    Molecule Shows Promise for MASH, Endometriosis, and Other Chronic Diseases < Yale School of Medicine

    Macrophages are the first line of defense of the immune system, helping fight infections and keeping tissues healthy. But in the context of some chronic diseases, these immune cells undergo changes and become pathogenic, helping drive disease and creating inflammation.

    Targeting these disease-induced macrophages without also killing off the protective ones has been challenging. But researchers have now discovered markers that are unique to pathogenic macrophages and have developed a molecule that can specifically eliminate them.

    They published their findings in the Journal of Clinical Investigation.

    While the team conducted these studies specifically in models of the liver disease known as metabolic dysfunction-associated steatohepatitis (MASH), non-small cell lung cancer (NSCLC), and endometriosis, the researchers are optimistic that the small molecule, called Bobcat339, and its future derivatives, could be a one-size-fits-all approach that treats a multitude of chronic diseases associated with inflammation.

    “We have found a very potent target associated with multiple chronic diseases, and we have a way to treat this target with Bobcat339,” says Yingqun Huang, MD, PhD, professor of obstetrics, gynecology & reproductive sciences at Yale School of Medicine and the study’s principal investigator. “And we are in the process of identifying even more potent molecules to treat these diseases.”

    Bobcat339 targets TET3 overexpression and mitigates chronic disease

    Across different chronic diseases, the affected part of the body often experiences cellular and molecular changes. Known as the disease microenvironment, this is what triggers healthy macrophages to become pathogenic.

    For the study, the researchers exposed healthy human and mouse macrophages to factors that mimicked different disease microenvironments. Doing so turned the macrophages pathogenic. Next, the researchers analyzed gene expression in these macrophages and found that the disease microenvironment upregulated expression of a gene called TET3. This in turn induced further changes that fueled inflammation and suppressed the immune system.

    These downstream changes, however, also made the macrophages susceptible to Bobcat339. While Bobcat339 is designed to degrade TET3 protein—the product of the TET3 gene—overexpression of TET3 alone is not enough to make the macrophages vulnerable to Bobcat339; the additional changes triggered by the disease environment are necessary for Bobcat339 to work.

    “Factors in the disease microenvironment not only induce TET3 overexpression in the macrophages but also change other genes. That creates a state in which the macrophages—which we call TET3-overexpressing macrophages—become sensitive to TET3 protein degradation,” Huang explains. “It’s a very specific population of macrophages—disease macrophages.”

    To the researchers, that suggested Bobcat339 should be able to target macrophages that are driving disease and spare healthy, protective macrophages. And additional experiments showed the molecule was capable of doing exactly that.

    The researchers found that Bobcat339 was successfully able to target and kill pathogenic macrophages without harming healthy ones. The team also tested the molecule in mouse models of MASH, NSCLC, and endometriosis. Across these three models, Bobcat339 decreased liver damage and liver fibrosis, reduced tumors and increased survival, and shrunk endometriotic lesions.

    Many individuals living with chronic diseases today still have few effective treatment options. In the future, Bobcat339 or its derivatives could be a new tool for helping patients manage their conditions.

    To assess the safety of Bobcat339, Huang’s team is conducting rigorous toxicity studies in animal models. So far, the molecule’s safety profile has been promising, she says. “If it continues to not show bad side effects, we can hopefully move onto human trials.”

    Continue Reading

  • Wagner’s Lohengrin set to debut in Taiwan at Weiwuying

    Wagner’s Lohengrin set to debut in Taiwan at Weiwuying

    Kaohsiung, Sept. 2 (CNA) The National Kaohsiung Center for the Arts (Weiwuying) will present Wagner’s Lohengrin in full on Thursday, marking its premiere in Taiwan and the first time a Wagnerian opera has been performed in southern Taiwan.

    With many years of experience, the Weiwuying team is confident in taking on the challenging 4.5 hour masterpiece, Chien Wen-pin (簡文彬), the performing center’s general and artistic director, told a news conference Tuesday.

    Chien, who also serves as conductor, will lead the production in collaboration with the creative team behind the 2014 staging of Lohengrin at Germany’s Opera on the Rhine. It will be performed four times from Thursday through Sunday.

    Lohengrin follows a mysterious knight who weds Elsa on the condition that she never ask his name. When the vow is broken, he must depart — revealing a haunting meditation on love, trust, power and desire.

    The production brings together leading vocalists from Taiwan and abroad. Vincent Wolfsteiner and Brenden Gunnell, two internationally renowned tenors known for their Wagnerian performances, share the title role of Lohengrin.

    Members of the 2014 Opera on the Rhine premiere join the production, including soprano Sylvia Hamvasi as Elsa and mezzo-soprano Heike Wessels as Ortrud.

    Taiwanese singers will make their Wagnerian Lohengrin debuts, with soprano Keng Li (耿立) and mezzo-soprano Weng Jo-pei (翁若珮) taking on the same roles, respectively.

    Meanwhile, emerging Taiwanese vocal talents Chao Fang-hao (趙方豪), James Lai (賴恩予), Chien Cheng-yu (簡正育), Hu Ting-wei (胡庭維), and Cheng Yu-hsuan (鄭又瑄) also join the cast, reflecting Weiwuying’s support for local talent on the international stage, the organizers said.

    (By Lin Chao-lien and Shih Hsiu-chuan)

    Enditem/AW

    Continue Reading

  • The use of echocardiography to identify acute and chronic changes in left ventricular function in hypertensive disorder of pregnancy | BMC Pregnancy and Childbirth

    The use of echocardiography to identify acute and chronic changes in left ventricular function in hypertensive disorder of pregnancy | BMC Pregnancy and Childbirth

  • FishelBartal M, Saade G, Tita AT, Sibai BM. Emerging concepts since the chronic hypertension and pregnancy trial. Am J Obstet Gynecol. 2023;229(5):516–21.

    Google Scholar 

  • Horgan R, HageDiab Y, Costantine M, Saade G, Sibai B. Diagnosis of hypertensive disorders in pregnancy. Am J Obstet Gynecol MFM. 2025;7(7):101693.

    PubMed 

    Google Scholar 

  • Patel VJ, Delano V, Juttu A, Adhora H, Zaheer A, Vargas L, et al. The Implications of Socioeconomic Status by ZIP Code on Maternal-Fetal Morbidity and Mortality in San Antonio, Texas. Cureus. 2025;16(2):e54636. https://doi.org/10.7759/cureus.54636. PMID: 38523982; PMCID: PMC10959557.

  • Fishel Bartal M, Sibai BMM. Eclampsia in the 21st century. Am J Obstet Gynecol. 2022;226(2):S1237–53.

    CAS 
    PubMed 

    Google Scholar 

  • Tranquilli AL, Brown MA, Zeeman GG, Dekker G, Sibai BM. The definition of severe and early-onset preeclampsia. Statements from the International Society for the Study of Hypertension in Pregnancy (ISSHP). Pregnancy Hypertens. 2013;3(1):44–7.

    PubMed 

    Google Scholar 

  • Robillard PY, Dekker G, Chaouat G, Scioscia M, Iacobelli S, Hulsey TC. Historical evolution of ideas on eclampsia/preeclampsia: A proposed optimistic view of preeclampsia. J Reprod Immunol. 2017;123:72–7.

    PubMed 
    PubMed Central 

    Google Scholar 

  • Jayawardena L, Mcnamara E. Diagnosis and management of pregnancies complicated by haemolysis, elevated liver enzymes and low platelets syndrome in the tertiary setting. Intern Med J. 2020;50(3):342–9.

    PubMed 

    Google Scholar 

  • Cagino K, Prabhu M, Sibai B. Is magnesium sulfate therapy warranted in all cases of late postpartum severe hypertension? A suggested approach to a clinical conundrum. Am J Obstet Gynecol. 2023;229(6):641–6.

    PubMed 

    Google Scholar 

  • Amro F, Sibai B. Management of hypertension in pregnancy. Semin Fetal Neonatal Med. 2020. https://doi.org/10.1016/j.siny.2020.101147.

    PubMed 

    Google Scholar 

  • Balhotra KS, Sibai BM. Aspirin dosage for preeclampsia prophylaxis: an argument for 81-mg dosing. American Journal of Obstetrics & Gynecology MFM. 2025;7(1S):101568.

    CAS 

    Google Scholar 

  • Rolnik DL, Poon LC, Syngelaki A, Wright D, O’Gorman N, de Paco MC, et al. Aspirin, birthweight, and large-for-gestational-age neonates: a secondary analysis of the ASPRE trial. BJOG An Int J Obstet Gynaecol. 2025. https://doi.org/10.1111/1471-0528.18263.

    Google Scholar 

  • Wertaschnigg D, Selvaratnam RJ, Rolnik DL, Davey M-A, Anil S, Mol BWJ, et al. Hypertensive disorders in pregnancy – trends over eight years: a population-based cohort study. Pregnancy Hypertens. 2022;28:60–5.

    PubMed 

    Google Scholar 

  • Wu P, Chew-Graham CA, Maas AH, Chappell LC, Potts JE, Gulati M, et al. Temporal changes in hypertensive disorders of pregnancy and impact on cardiovascular and obstetric outcomes. Am J Cardiol. 2020;125(10):1508–16.

    PubMed 

    Google Scholar 

  • Runkle JD, Matthews JL, Sparks L, McNicholas L, Sugg MM. Racial and ethnic disparities in pregnancy complications and the protective role of greenspace: a retrospective birth cohort study. Sci Total Environ. 2022;808:152145. https://doi.org/10.1016/j.scitotenv.2021.152145. Epub 2021 Dec 3. PMID: 34871679.

  • MacDorman MF, Thoma M, Declcerq E, Howell EA. Racial and ethnic disparities in maternal mortality in the United States using enhanced vital records, 2016–2017. Am J Public Health. 2021;111:1673–81.

    PubMed 
    PubMed Central 

    Google Scholar 

  • Voerman E, Santos S, Inskip H, Amiano P, Barros H, Charles MA, et al. Association of gestational weight gain with adverse maternal and infant outcomes. JAMA. 2019;321(17):1702–15.

    PubMed 
    PubMed Central 

    Google Scholar 

  • Dantas EMDM, Pereira FVM, Queiroz JW, Dantas DLDM, Monteiro GRG, Duggal P, et al. Preeclampsia is associated with increased maternal body weight in a northeastern Brazilian population. BMC Pregnancy Childbirth. 2013. https://doi.org/10.1186/1471-2393-13-159.

    PubMed 
    PubMed Central 

    Google Scholar 

  • Singh S, Gupta V, Rawal S, Parmar S, Sethia S, Sharma R. The impact of maternal nutrition status on maternal and fetal outcomes: a prospective observational study. J Pharm Bioallied Sci. 2025;17(Suppl 1):S346–9.

    PubMed 
    PubMed Central 

    Google Scholar 

  • O’Connor SG, Habre R, Bastain TM, Toledo-Corral CM, Gilliland FD, Eckel SP, et al. Within-subject effects of environmental and social stressors on pre- and post-partum obesity-related biobehavioral responses in low-income Hispanic women: protocol of an intensive longitudinal study. BMC Public Health. 2019. https://doi.org/10.1186/s12889-019-6583-x.

    PubMed 
    PubMed Central 

    Google Scholar 

  • Bombard JM, Dietz PM, Galavotti C, England LJ, Tong VT, Hayes DK, et al. Chronic diseases and related risk factors among low-income mothers. Matern Child Health J. 2012;16(1):60–71.

    PubMed 

    Google Scholar 

  • Bellamy L, Casas JP, Hingorani AD, Williams DJ. Pre-eclampsia and risk of cardiovascular disease and cancer in later life: systematic review and meta-analysis. Br Med J. 2007;335(7627):974–7.

    Google Scholar 

  • Auger N, Potter BJ, He S, Healy-Profitós J, Schnitzer ME, Paradis G. Maternal cardiovascular disease 3 decades after preterm birth: longitudinal cohort study of pregnancy vascular disorders. Hypertension. 2020. https://doi.org/10.1161/HYPERTENSIONAHA.119.14221.

    PubMed 

    Google Scholar 

  • White WM, Mielke MM, Araoz PA, Lahr BD, Bailey KR, Jayachandran M, et al. A history of preeclampsia is associated with a risk for coronary artery calcification 3 decades later. Am J Obstet Gynecol. 2016;214(4):519.e1-519.e8.

    PubMed 

    Google Scholar 

  • Fields JA, Garovic VD, Mielke MM, Kantarci K, Jayachandran M, White WM, et al. Preeclampsia and cognitive impairment later in life. Am J Obstet Gynecol. 2017;217(1):74.e1-74.e11.

    PubMed 

    Google Scholar 

  • Shahul S, Rhee J, Hacker MR, Gulati G, Mitchell JD, Hess P, et al. Subclinical left ventricular dysfunction in preeclamptic women with preserved left ventricular ejection fraction: a 2D speckle-tracking imaging study. Circ Cardiovasc Imaging. 2012;5(6):734–9.

    PubMed 

    Google Scholar 

  • Lewandowski AJ, Augustine D, Lamata P, Davis EF, Lazdam M, Francis J, et al. Preterm heart in adult life: cardiovascular magnetic resonance reveals distinct differences in left ventricular mass, geometry, and function. Circulation. 2013;127(2):197–206.

    PubMed 

    Google Scholar 

  • Shah LM, Varma B, Nasir K, Walsh MN, Blumenthal RS, Mehta LS, et al. Reducing disparities in adverse pregnancy outcomes in the United States. Am Heart J. 2021;242:92–102.

    PubMed 

    Google Scholar 

  • Lin Y, Sun J, Fang S, Li C, Yang X, Yuan H, et al. Association between novel inflammatory biomarkers SII, SIRI, and obesity in sedentary adults: NHANES 2007–2020. Sci Rep. 2025;15(1):22300.

    PubMed 
    PubMed Central 

    Google Scholar 

  • Lacsa JEM. The hidden burden: inflammatory bowel disease and cardiovascular mortality in underreported populations. Int J Cardiol Cardiovasc Risk Prevent. 2025. https://doi.org/10.1016/j.ijcrp.2025.200449.

    Google Scholar 

  • Mor-Avi V, Lang RM, Badano LP, Belohlavek M, Cardim NM, Derumeaux G, et al. Current and evolving echocardiographic techniques for the quantitative evaluation of cardiac mechanics: ASE/EAE consensus statement on methodology and indications endorsed by the Japanese society of echocardiography. Eur J Echocardiogr. 2011;12(3):167–205.

    PubMed 

    Google Scholar 

  • Nagueh SF, Smiseth OA, Appleton CP, Byrd BF, Dokainish H, Edvardsen T, et al. Recommendations for the evaluation of left ventricular diastolic function by echocardiography: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr. 2016;29(4):277–314.

    PubMed 

    Google Scholar 

  • Gan GCH, Kadappu KK, Bhat A, Fernandez F, Gu KH, Cai L, et al. Left atrial strain is the best predictor of adverse cardiovascular outcomes in patients with chronic kidney disease. J Am Soc Echocardiogr. 2021;34(2):166–75.

    PubMed 

    Google Scholar 

  • Gan GCH, Bhat A, Chen HHL, Fernandez F, Byth K, Eshoo S, et al. Determinants of LA reservoir strain: independent effects of LA volume and LV global longitudinal strain. Echocardiography. 2020;37(12):2018–28.

    PubMed 

    Google Scholar 

  • Ferruzzi GJ, Campanile A, Visco V, Loria F, Mone P, Masarone D, et al. Subclinical left ventricular dysfunction assessed by global longitudinal strain correlates with mild cognitive impairment in hypertensive patients. Hypertens Res. 2025;48(5):1768–78.

    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Vaught AJ, Kovell LC, Szymanski LM, Mayer SA, Seifert SM, Vaidya D, et al. Acute cardiac effects of severe pre-eclampsia. J Am Coll Cardiol. 2018;72(1):1–11.

    PubMed 
    PubMed Central 

    Google Scholar 

  • Patten IS, Rana S, Shahul S, Rowe GC, Jang C, Liu L, et al. Cardiac angiogenic imbalance leads to peripartum cardiomyopathy. Nature. 2012;485(7398):333–8.

    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Vasapollo B, Novelli GP, Maellaro F, Gagliardi G, Pais M, Silvestrini M, et al. Maternal cardiovascular profile is altered in the preclinical phase of normotensive early and late intrauterine growth restriction. Am J Obstet Gynecol. Am J Obstet Gynecol. 2025;232(3):312.e1–312.e21

  • Galderisi M, Cosyns B, Edvardsen T, Cardim N, Delgado V, Di Salvo G, et al. Standardization of adult transthoracic echocardiography reporting in agreement with recent chamber quantification, diastolic function, and heart valve disease recommendations: an expert consensus document of the European Association of Cardiovascular Imaging. Eur Heart J Cardiovasc Imaging. 2017;18(12):1301–10.

    PubMed 

    Google Scholar 

  • Muldoon KA, McLean C, El-Chaár D, Corsi DJ, Rybak N, Dagvadorj A, et al. Persisting risk factors for preeclampsia among high-risk pregnancies already using prophylactic aspirin: a multi-country retrospective investigation. J Matern Fetal Neonatal Med. 2023. https://doi.org/10.1080/14767058.2023.2200879.

    PubMed 

    Google Scholar 

  • Frost AL, Suriano K, Aye CYL, Leeson P, Lewandowski AJ. The immediate and long-term impact of preeclampsia on offspring vascular and cardiac physiology in the preterm infant. Front Pediatr. 2021;9:625726.

    PubMed 
    PubMed Central 

    Google Scholar 

  • Davis EF, Lewandowski AJ, Aye C, Williamson W, Boardman H, Huang RC, et al. Clinical cardiovascular risk during young adulthood in offspring of hypertensive pregnancies: insights from a 20-year prospective follow-up birth cohort. BMJ Open. 2015. https://doi.org/10.1136/bmjopen-2015-008136.

    PubMed 
    PubMed Central 

    Google Scholar 

  • Lewandowski AJ, Leeson P. Preeclampsia, prematurity and cardiovascular health in adult life. Early Hum Dev. 2014;90(11):725–9.

    PubMed 

    Google Scholar 

  • Halliday BP, Senior R, Pennell DJ. Assessing left ventricular systolic function: from ejection fraction to strain analysis. Eur Heart J. 2021;42(7):789–97.

    PubMed 

    Google Scholar 

  • Stott D, Papastefanou I, Paraschiv D, Clark K, Kametas NA. Serial hemodynamic monitoring to guide treatment of maternal hypertension leads to reduction in severe hypertension. Ultrasound Obstet Gynecol. 2017;49(1):95–103.

    CAS 
    PubMed 

    Google Scholar 

  • di Pasquo E, Giannubilo SR, Valentini B, Salvi S, Rullo R, Fruci S, et al. The “Preeclampsia and Hypertension Target Treatment” study: a multicenter prospective study to evaluate the effectiveness of the antihypertensive therapy based on maternal hemodynamic findings. Am J Obstet Gynecol MFM. 2024. https://doi.org/10.1016/j.ajogmf.2024.101368.

    PubMed 

    Google Scholar 

  • Abalos E, Duley L, Steyn DW, Gialdini C. Antihypertensive drug therapy for mild to moderate hypertension during pregnancy. Cochrane Database Syst Rev. 2018;2018(10):CD002252. https://doi.org/10.1002/14651858.CD002252.pub4. PMID: 30277556; PMCID: PMC6517078.

  • Chaemsaithong P, Cuenca-Gomez D, Plana MN, Gil MM, Poon LC. Does low-dose aspirin initiated before 11 weeks’ gestation reduce the rate of preeclampsia? Am J Obstet Gynecol. 2020;222(5):437–50.

    CAS 
    PubMed 

    Google Scholar 

  • Oliveira MFRA, Rocha WEM, Soares JD, L’Armée VMFS, Martins MPG, Rocha AM, et al. Impact of hypertension history and blood pressure at presentation on cardiac remodeling and mortality in aortic dissection. Front Cardiovasc Med. 2021;8:803283.

    PubMed 

    Google Scholar 

  • Gibbone E, Huluta I, Wright A, Nicolaides KH, Charakida M. Maternal cardiac function at midgestation and development of preeclampsia. J Am Coll Cardiol. 2022;79(1):52–62.

    PubMed 

    Google Scholar 

  • Plummer MD, Andraweera PH, Garrett A, Leemaqz S, Wittwer M, Aldridge E, et al. Hypertensive disorders of pregnancy and later cardiovascular disease risk in mothers and children. J Dev Orig Health Dis. 2021;12(4):555–60.

    CAS 
    PubMed 

    Google Scholar 

  • Arnott C, Patel S, Hyett J, Jennings G, Woodward M, Celermajer DS. Women and cardiovascular disease: pregnancy, the forgotten risk factor. Heart Lung Circ. 2020;29(5):662–7.

    PubMed 

    Google Scholar 

  • Andraweera PH, Lassi ZS, Pathirana MM, Plummer MD, Dekker GA, Roberts CT, et al. Pregnancy complications and cardiovascular disease risk perception: a qualitative study. PLoS ONE. 2022;17(7):e0271722. https://doi.org/10.1371/journal.pone.0271722.

    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Oliver-Williams C, Stevens D, Payne RA, Wilkinson IB, Smith GCS, Wood A. Association between hypertensive disorders of pregnancy and later risk of cardiovascular outcomes. BMC Med. 2022;20(1):19. https://doi.org/10.1186/s12916-021-02218-8.

    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Vaught AJ, Minhas A, Boyer T, Debrosse A, Sharma G, Vaidya D, et al. Incidence of essential hypertension but not echocardiographic abnormalities at four years with a history of preeclampsia with severe features. Pregnancy Hypertens. 2021;25:185–90.

    PubMed 
    PubMed Central 

    Google Scholar 

  • Vasapollo B, Zullino S, Novelli GP, Farsetti D, Ottanelli S, Clemenza S, et al. Maternal hemodynamics from preconception to delivery: research and potential diagnostic and therapeutic implications: position statement by Italian Association of Preeclampsia and Italian Society of Perinatal Medicine. Am J Perinatol. 2024;41(14):1999–2013. https://doi.org/10.1055/a-2267-3994.

    PubMed 

    Google Scholar 

  • Mulder EG, Ghossein-Doha C, Cauffman E, Lopes Van Balen VA, Schiffer VMMM, Alers RJ, et al. Preventing Recurrent Preeclampsia by Tailored Treatment of Nonphysiologic Hemodynamic Adjustments to Pregnancy. Hypertension. 2021;77(6):2045–53.

  • Vasapollo B, Novelli GP, Valensise H. Total vascular resistance and left ventricular morphology as screening tools for complications in pregnancy. Hypertension. 2008;51(4 PART 2 SUPPL.):1020–6.

    CAS 
    PubMed 

    Google Scholar 

  • Novelli GP, Vasapollo B, Gagliardi G, Tiralongo GM, Pisani I, Manfellotto D, et al. Left ventricular midwall mechanics at 24 weeks’ gestation in high-risk normotensive pregnant women: relationship to placenta-related complications of pregnancy. Ultrasound Obstet Gynecol. 2012;39(4):430–7.

    CAS 
    PubMed 

    Google Scholar 

  • Demirci M, Özdemir B, Zengin G, Oğuz M, Sünbül M, Sayar N. Cardiac dysfunction and 5-year mortality in patients with systemic sclerosis and interstitial lung disease: a speckle-tracking echocardiography study. J Clin Ultrasound. 2025. https://doi.org/10.1002/jcu.24094.

    PubMed 

    Google Scholar 

  • Vera A, Lanaspa A, Jiménez O, Navarro A, Basurte MT, Beunza M, et al. Reduced left atrial strain is associated with worse outcomes in coronary embolism. Heart Vessels. 2025 May 28. https://doi.org/10.1007/s00380-025-02561-3. Epub ahead of print

Continue Reading

  • Silanna UV Unveils Enhanced Next Gen SF2 230nm Far UVC LED With 2x Intensity

    Silanna UV Unveils Enhanced Next Gen SF2 230nm Far UVC LED With 2x Intensity

    Optimized for Water/Gas Sensing and Disinfection, TO-can Package, 2X Temperature Stability

    BRISBANE, Australia, Sept. 2, 2025 /PRNewswire/ — Silanna UV is pleased to announce the release of its next generation Far UVC LED, the SF2-3T9B5L1-TB, which exceeds even the popular SF1 series, with UVC wavelengths down to 230nm (typical 233nm); doubled output power; and 2x improvement in temperature stability. This new SF2 UVC LED is encapsulated in a standard compact Transistor Outline (TO-can) package.




    Silanna UV SF2 230nm Far UVC LED






    Silanna UV SF2 230nm Far UVC LED

    The SF2 is designed for precise detection and reliable disinfection in demanding environments, with the collimated ball lens providing a 17° effective beam angle. It is ideal for detection of nitrate (NO3) and nitrite (NO2) in water, and detection of carbon dioxide (CO2) and Nitric Oxide (NO) in gas. These features make this far UVC LED excellent for applications such as chemical and biological analysis, water quality monitoring, gas sensing, liquid chromatography, and disinfection.

    SF2 Far UVC LED: Stability, Environmental Safety, Durability, High Output
    These LEDs have an environmental advantage, as they contain no mercury, and the LEDs are far more robust than traditional UV lamps. The TO-can package format, with industry standard TO-39 footprint, consists of a header and a cap that together form a hermetically-sealed package. Electrostatic Discharge (ESD) protection is integrated.

    The SF2 LED improves Far UVC products by doubling typical radiant intensity to 2 mw/Sr. But at the same time, this new product’s improved temperature stability minimizes the impact when the temperature changes, keeping output power and wavelength stable to ensure quality detection readings. Thus, this product sets a new benchmark in Far UVC LED technology.

    Meet Silanna UV at September 2025 Industry Events to Find Out More About 230nm LED
    Silanna UV will attend the following events in September 2025:

    • 2025 IUVA World Congress, in Lisbon, Portugal, from September 7-10, 2025
    • CIOE 2025, in Shenzhen, China, from September 10-12, 2025
    • WWEM, in the UK, from September 17-18, 2025
    • Microelectronics UK, in the UK, from September 24-25, 2025

    To attend these events and learn more about Silanna’s patented UVC LED monitoring and disinfection technology, please contact the Sales Team at [email protected] For more information about the SF2 Far UVC 230nm series, please visit https://silannauv.com/products/.

    About Silanna UV
    The Silanna Group is an Australian semiconductor manufacturer established in 2006. Privately funded since being acquired from Peregrine Semiconductor in 2008, Silanna UV is an ISO 9001:2015 certified solution provider for UVC LED manufacturing. Based in Brisbane, Australia, Silanna UV provides far UVC light sources for water quality sensors, gas sensors, disinfection, and HPLC (High-performance liquid chromatography) applications. Silanna UV’s innovative approach allows UV LED technology to push toward shorter wavelengths, from 230nm to 265nm, including deep UVC and far UVC ranges. The company holds unique epitaxy technology and holds patents related to UV LED technology. With its unique UV LED technology, Silanna UV strives to create new possibilities by pushing UV wavelength boundaries to the limit. To learn more, please visit https://silannauv.com/.

    Media Contact:
    Kayla Lee
    [email protected]
    0228825577

    SOURCE Silanna UV

    Continue Reading